The one book to read to understand your industry
These offbeat classics, picked by people working in key sectors, can act as spiritual guidebooks, revealing the subtler ...
Nature15d
Stem cells head to the clinic: treatments for cancer, diabetes and Parkinson’s disease could soon be here
More than 100 clinical trials put stem cells for regenerative medicine to the test. It’s a turning point for a field beset ...
Vertex Pharmaceuticals Inc. stock rises Friday, still underperforms market
This was the stock's third consecutive day of gains.
Vertex Pharmaceuticals: Jim Cramer Fires A Warning Shot But I Remain Invested
Vertex Pharmaceuticals offers promising opportunities in pain management, cystic fibrosis treatments, and a diversified ...
Levi & Korsinsky Announces an Investigation on Behalf of Vertex Pharmaceuticals Incorporated (VRTX) Shareholders Who May Have Been Affected by Fraud
NEW YORK, NY / ACCESSWIRE / January 3, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Vertex ...
Should You Buy Vertex Pharmaceuticals on the Dip Before Potentially Enormous News in January 2025?
Different genetic mutations cause different problems with this particular protein -- so CFTR modulators generally don't work ...
Vertex Pharmaceuticals’ (VRTX) Hold Rating Reiterated at Needham & Company LLC
Needham & Company LLC reaffirmed their hold rating on shares of Vertex Pharmaceuticals (NASDAQ:VRTX – Free Report) in a ...
Levi & Korsinsky Reminds Vertex Pharmaceuticals Investors of the Ongoing Investigation into Potential Violations of Securities Laws - VRTX
NEW YORK, NY / ACCESSWIRE / January 2, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Vertex ...
ETF Daily News11d
Vertex Pharmaceuticals (NASDAQ:VRTX) Given New $430.00 Price Target at Scotiabank
Other equities research analysts have also issued reports about the company. Morgan Stanley raised their price objective on Vertex Pharmaceuticals from $473.00 to $476.00 and gave the stock an ...
The Motley Fool8d
Vertex Pharmaceuticals Stock Is Down 13%. Here's Why You Should Buy the Dip
Vertex Pharmaceuticals is trying to diversify its ... Judging by the results, the company may not have a winner on its hands. The candidate is already being considered for approval by regulators ...
Yahoo Finance10d
Vertex Pharmaceuticals (VRTX) Gains But Lags Market: What You Should Know
Vertex Pharmaceuticals (VRTX ... we can consider positive estimate revisions a sign of optimism about the company's business outlook. Research indicates that these estimate revisions are directly ...